Platelet-Mediated Thrombosis
Key result
Personalized antiplatelet therapy based on point-of-care platelet function testing lacks strong prospective evidence for reducing ischemic events in patients with high-risk coronary artery disease.
Why the study?
Does personalized antiplatelet therapy based on point-of-care assessment of platelet function reduce ischemic event occurrences in patients with high-risk coronary artery disease?
Population
Patients with high-risk coronary artery disease, including those undergoing coronary artery stenting
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Does not support routine point-of-care testing to personalize antiplatelet therapy in high-risk CAD; leaves open need for rigorous prospective trials.
Structured PICO
Does personalized antiplatelet therapy based on point-of-care assessment of platelet function reduce ischemic event occurrences in patients with high-risk coronary artery disease?
P
Population
Patients with high-risk coronary artery disease, including those undergoing coronary artery stenting
I
Intervention
Personalized antiplatelet therapy based on point-of-care assessment of platelet function
O
Outcome
Ischemic event occurrences
Despite observational data linking platelet reactivity to clinical events, randomized trials have not shown a benefit for personalized antiplatelet therapy based on point-of-care testing in reducing ischemic events.
Limitations
- Important limitations were associated with the prospective, randomized trials evaluated.
Cite This Study
Gurbel et al. (2016) conducted a review in High-risk coronary artery disease. Personalized antiplatelet therapy based on point-of-care platelet function testing was evaluated. Personalized antiplatelet therapy based on point-of-care platelet function testing lacks strong prospective evidence for reducing ischemic events in patients with high-risk coronary artery disease.